GlassScriptPhysician profile
James Rex Mcnutt
NPI 1790088623
$6,391.07
in general payments reported to CMS, 2019-2025
27 companies · $5,293 in 2025
The $5,293 reported for 2025 was more than what 99% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $122 · 2022: $58.91 · 2023: $159 · 2024: $759 · 2025: $5,293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,531 · Consulting Fee: $1,434 · Education: $246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,530.56 |
| Consulting Fee | $1,434.00 |
| Education | $245.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,121.95 | 2024-2025 | |
| Glaxosmithkline, LLC. | $682.37 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $571.83 | 2022-2025 | Fasenra, Airsupra, Tezspire |
| Insmed, INC. | $503.33 | 2024-2025 | Arikayce, Brinsupri |
| Grifols USA, LLC | $242.82 | 2023-2025 | Prolastin-C Liquid |
| Abbvie INC. | $228.48 | 2025 | |
| Amgen INC. | $210.33 | 2024-2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.95 | 2024-2025 | Ofev, Jascayd, Spiriva Respimat |
| Takeda Pharmaceuticals U.S.A., INC. | $177.29 | 2025 | Glassia |
| Merck Sharp & Dohme LLC | $174.40 | 2024-2025 | Winrevair |
| Regeneron Healthcare Solutions, INC. | $168.95 | 2024-2025 | Dupixent |
| Bayer Healthcare Pharmaceuticals INC. | $162.24 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $160.10 | 2024-2025 | Uptravi, Opsumit |
| Sanofi-Aventis U.S. LLC | $146.98 | 2024-2025 | |
| Harmony Biosciences LLC | $135.93 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $134.20 | 2024-2025 | Tyvaso, Remodulin, Orenitram |
| Verona Pharma, INC. | $82.46 | 2025 | Ohtuvayre |
| Electromed, INC. | $56.61 | 2024-2025 | Smartvest |
| Itamar Medical INC | $53.98 | 2025 | Watchpatone |
| Axsome Therapeutics, INC. | $46.45 | 2023-2024 | Sunosi |
| Jazz Pharmaceuticals INC. | $32.77 | 2025 | |
| Inspire Medical Systems, INC. | $25.40 | 2025 | Inspire |
| Pulmonx Corporation | $20.29 | 2023 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Novartis Pharmaceuticals Corporation | $19.67 | 2025 | |
| Shionogi INC | $19.38 | 2025 | Fetroja |
| Baxter Healthcare | $18.36 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Inogen, INC. | $3.55 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Mcnutt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.